<DOC>
	<DOCNO>NCT02995772</DOCNO>
	<brief_summary>This study compare long term outcome stage IIIB/C IV breast cancer patient treat neoadjuvant hormonal therapy ( NAHT ) treat neoadjuvant chemotherapy ( NACT )</brief_summary>
	<brief_title>Neoadjuvant Hormonal Therapy Compared Neoadjuvant Chemotherapy Stage IIIB/C IV Breast Cancer Patients</brief_title>
	<detailed_description>This study compare long term outcome stage IIIB/C IV breast cancer patient treat neoadjuvant hormonal therapy ( NAHT ) treat neoadjuvant chemotherapy ( NACT ) 2011 2016 . The primary end point overall survival ( OS ) progression free survival ( PFS ) Kaplan Meier . This study approve Ethical Committee Dharmais National Cancer Hospital .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>IIIB/C IV stage breast cancer receive neoadjuvant hormonal therapy neoadjuvant chemotherapy first second biopsy ( surgery ) within 6 month mastectomy treatment pregnant disagree enter study give hormonal therapy chemotherapy study contraindication SOB premenopausal patient</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>